Arrowhead Pharmaceuticals (ARWR) Competitors $18.71 +0.11 (+0.59%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARWR vs. ACAD, FOLD, BHC, PRGO, RARE, ITCI, ROIV, ASND, LEGN, and ELANShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC), Perrigo (PRGO), Ultragenyx Pharmaceutical (RARE), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry. Arrowhead Pharmaceuticals vs. ACADIA Pharmaceuticals Amicus Therapeutics Bausch Health Companies Perrigo Ultragenyx Pharmaceutical Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Arrowhead Pharmaceuticals (NASDAQ:ARWR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Do analysts rate ARWR or ACAD? Arrowhead Pharmaceuticals currently has a consensus price target of $45.33, indicating a potential upside of 142.29%. ACADIA Pharmaceuticals has a consensus price target of $25.56, indicating a potential upside of 57.11%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.65 Does the MarketBeat Community prefer ARWR or ACAD? ACADIA Pharmaceuticals received 354 more outperform votes than Arrowhead Pharmaceuticals when rated by MarketBeat users. Likewise, 73.20% of users gave ACADIA Pharmaceuticals an outperform vote while only 65.41% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes53965.41% Underperform Votes28534.59% ACADIA PharmaceuticalsOutperform Votes89373.20% Underperform Votes32726.80% Which has stronger valuation and earnings, ARWR or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$19.65M118.38-$205.27M-$4.67-4.01ACADIA Pharmaceuticals$726.44M3.73-$61.29M$0.7820.86 Which has more volatility & risk, ARWR or ACAD? Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Is ARWR or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -152.95% -63.93% ACADIA Pharmaceuticals 13.83%25.83%14.71% Do insiders and institutionals have more ownership in ARWR or ACAD? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor ARWR or ACAD? In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 12 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.08 beat ACADIA Pharmaceuticals' score of 0.04 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryACADIA Pharmaceuticals beats Arrowhead Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.31B$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-4.0110.78135.4117.82Price / Sales118.38243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book6.985.474.674.68Net Income-$205.27M$153.61M$119.07M$226.08M7 Day Performance-12.61%-2.00%-1.83%-1.04%1 Month Performance-8.69%-7.46%-3.60%1.04%1 Year Performance-34.05%31.82%31.66%26.28% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.574 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$19.65M-4.01400Upcoming EarningsAnalyst ForecastACADACADIA Pharmaceuticals3.9106 of 5 stars$16.27+0.4%$25.56+57.1%-29.0%$2.71B$726.44M20.86510Insider TradeAnalyst RevisionFOLDAmicus Therapeutics4.6538 of 5 stars$9.59+0.7%$17.63+83.8%-13.1%$2.84B$493.67M-28.21480BHCBausch Health Companies3.3164 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B-17.0720,270Positive NewsPRGOPerrigo4.9792 of 5 stars$27.15-0.3%$37.00+36.3%-10.8%$3.70B$4.66B-23.209,140Positive NewsRAREUltragenyx Pharmaceutical4.6377 of 5 stars$46.40+2.8%$86.69+86.8%+17.9%$4.28B$434.25M-7.171,276ITCIIntra-Cellular Therapies4.4673 of 5 stars$85.64+2.7%$97.23+13.5%+46.2%$9.08B$464.37M-98.44560Positive NewsROIVRoivant Sciences3.2837 of 5 stars$11.49+1.6%$17.93+56.0%+30.6%$8.50B$129.13M2.03860ASNDAscendis Pharma A/S3.0129 of 5 stars$124.380.0%$191.77+54.2%+32.7%$7.54B$288.08M-15.39640Analyst UpgradeLEGNLegend Biotech1.7588 of 5 stars$40.14+4.5%$81.46+102.9%-33.7%$7.32B$520.18M-42.251,800Analyst RevisionHigh Trading VolumeELANElanco Animal Health4.1136 of 5 stars$13.44+1.0%$17.14+27.6%+13.1%$6.64B$4.42B33.609,300 Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Bausch Health Companies Alternatives Perrigo Alternatives Ultragenyx Pharmaceutical Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARWR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
